Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia  Abdellah Aouifi, MD, Pascale Blanc, MD, Vincent.

Published byHugh Hood Modified over 5 years ago

Similar presentations

Presentation on theme: "Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia  Abdellah Aouifi, MD, Pascale Blanc, MD, Vincent."— Presentation transcript:

1 Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia  Abdellah Aouifi, MD, Pascale Blanc, MD, Vincent Piriou, MD, PhD, Olivier H Bastien, MD, Patrick Ffrench, MD, Michel Hanss, MD, Jean- Jacques Lehot, MD, PhD  The Annals of Thoracic Surgery  Volume 71, Issue 2, Pages (February 2001) DOI: /S (00)

2 Fig 1 Algorithm for anticoagulation management in patients with HIT type II scheduled for cardiac surgery with CPB. (CPB = cardiopulmonary bypass; HIT = heparin-induced thrombocytopenia.) The Annals of Thoracic Surgery  , DOI: ( /S (00) )

Download ppt "Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia  Abdellah Aouifi, MD, Pascale Blanc, MD, Vincent."

Similar presentations

Impact of cardiac surgery using cardiopulmonary bypass on course of chronic lymphatic leukemia: a case-control study Evgenij V Potapov, MD, Heinz R Zurbrügg,

Impact of cardiac surgery using cardiopulmonary bypass on course of chronic lymphatic leukemia: a case-control study Evgenij V Potapov, MD, Heinz R Zurbrügg,
Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia  Abdellah Aouifi, MD, Pascale Blanc, MD, Vincent.

Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia  Abdellah Aouifi, MD, Pascale Blanc, MD, Vincent.
Leena Khaitan, MD, Francis P Sutter, Scott M Goldman, MD 

Leena Khaitan, MD, Francis P Sutter, Scott M Goldman, MD 
The Myocardial Protective Effects of a Moderate-Potassium Blood Cardioplegia in Pediatric Cardiac Surgery: A Randomized Controlled Trial  Yang Liu, MD,

The Myocardial Protective Effects of a Moderate-Potassium Blood Cardioplegia in Pediatric Cardiac Surgery: A Randomized Controlled Trial  Yang Liu, MD,
Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences  Jean Deslauriers, MD, Jocelyn Grégoire,

Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences  Jean Deslauriers, MD, Jocelyn Grégoire,
A Closed Perfusion System With Heparin Coating and Centrifugal Pump Improves Cardiopulmonary Bypass Biocompatibility in Elderly Patients  Lena Lindholm,

A Closed Perfusion System With Heparin Coating and Centrifugal Pump Improves Cardiopulmonary Bypass Biocompatibility in Elderly Patients  Lena Lindholm,
Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized study  Song Wan, MD, PhD, Jean-Louis.

Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized study  Song Wan, MD, PhD, Jean-Louis.
Conservative treatment for postintubation tracheobronchial rupture

Conservative treatment for postintubation tracheobronchial rupture
P. W. Boonstra, MD, PhD, Y. J. Gu, MD, PhD, C. Akkerman, BSc, J

P. W. Boonstra, MD, PhD, Y. J. Gu, MD, PhD, C. Akkerman, BSc, J
Management of catheter-induced pulmonary artery perforation: a rare complication in cardiovascular operations  Srikrishna Sirivella, MD, Isaac Gielchinsky,

Management of catheter-induced pulmonary artery perforation: a rare complication in cardiovascular operations  Srikrishna Sirivella, MD, Isaac Gielchinsky,
Continuous pulmonary perfusion during cardiopulmonary bypass prevents lung injury in infants  Takaaki Suzuki, MD, Toyoki Fukuda, MD, Tsutomu Ito, MD,

Continuous pulmonary perfusion during cardiopulmonary bypass prevents lung injury in infants  Takaaki Suzuki, MD, Toyoki Fukuda, MD, Tsutomu Ito, MD,
James L Zellner, MD, Scott B Kribbs, BS, B

James L Zellner, MD, Scott B Kribbs, BS, B
Bashir M Matata, PhD, Andrzej W Sosnowski, MD, Manuel Galiñanes 

Bashir M Matata, PhD, Andrzej W Sosnowski, MD, Manuel Galiñanes 
Prevalence of Heparin/Platelet Factor 4 Antibodies Before and After Cardiac Surgery  Brendan M. Everett, MD, Robert Yeh, MD, Shi Yin Foo, MD, PhD, David.

Prevalence of Heparin/Platelet Factor 4 Antibodies Before and After Cardiac Surgery  Brendan M. Everett, MD, Robert Yeh, MD, Shi Yin Foo, MD, PhD, David.
Assessment of heparin anticoagulation: comparison of two commercially available methods  Hanne I Flom-Halvorsen, PhD, Eivind Øvrum, MD, PhD, Michel Abdelnoor,

Assessment of heparin anticoagulation: comparison of two commercially available methods  Hanne I Flom-Halvorsen, PhD, Eivind Øvrum, MD, PhD, Michel Abdelnoor,
What is the marginal cost for marginal risk in cardiac surgery?

What is the marginal cost for marginal risk in cardiac surgery?
Steven R. Gundry, MD, Matthew A. Romano, MD, O

Steven R. Gundry, MD, Matthew A. Romano, MD, O
Current determinants of operative mortality in 1400 patients requiring aortic valve replacement  Ines Florath, PhD, Ulrich P Rosendahl, MD, Amir Mortasawi,

Current determinants of operative mortality in 1400 patients requiring aortic valve replacement  Ines Florath, PhD, Ulrich P Rosendahl, MD, Amir Mortasawi,
Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only  Thierry P Carrel, MD, Mike Schwanda, MD,

Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only  Thierry P Carrel, MD, Mike Schwanda, MD,
Susanne Lison, MD, Michael Spannagl, MD, PhD, Wulf Dietrich, MD, PhD 

Susanne Lison, MD, Michael Spannagl, MD, PhD, Wulf Dietrich, MD, PhD 

Similar presentations

Ads by Google